Social Determinants of Health and Long‑Term Joblessness Among Severe COVID‑19 Survivors: Secondary Analysis of a Nationwide 2‑Year Prospective Cohort (COVID-19 Recovery Study II)
Akira Kawauchi(Maebashi Red Cross Hospital), On behalf of the COVID-19 Recovery Study II (CORES II) Study Group., Arisa Iba(National Center for Global Health and Medicine), Hideki Yoshida(Kyoto Prefectural University of Medicine), Katsuji Teruya(National Center for Global Health and Medicine), Toshiyuki Harada(Hokkaido hospital), Junji Hatakeyama(Osaka University of Pharmaceutical Sciences), Yoko Muto(National Center for Global Health and Medicine), Nobuyuki Nosaka(Tokyo Medical and Dental University), MARIKO HOSOZAWA(National Center for Global Health and Medicine), T Nishida(Osaka Prefectural Medical Center), Hayato Taniguchi(Hiroshima University), Kensuke Nakamura(Hitachi General Hospital), Hiroshi Kamijo(Shinshu University Hospital), Hideaki Kato(Yokohama City University Hospital), Snigdha Jain(Yale University), Tatsuya Fuchigami(University of the Ryukyus University Hospital), Yuichi Sato(Tokyo Metropolitan Tama Medical Center), Kohei Ota(Hiroshima University), Miyuki Hori(Public Health Department), Tomohiro Asahi(Naha City Hospital), Katrina Hauschildt(Johns Hopkins University), Shuhei Maruyama(Kansai Medical University), Shinichiro Morioka(National Center for Global Health and Medicine), Satoshi Miike(Yokohama City Seibu Hospital), Mitsunobu Nakamura(Maebashi Red Cross Hospital), Takeshi Hattori(National Hospital Organization Hokkaido Medical Center), Hiroyasu Iso(National Center for Global Health and Medicine), Shigeki Fujitani(St. Marianna University School of Medicine), Futoshi Nagashima(Toyooka Hospital), Taku Oshima(Chiba University)
Cited by 0
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)
|Annals of Oncology|2012|555
Two‐component system VraSR positively modulates the regulation of cell‐wall biosynthesis pathway in <i>Staphylococcus aureus</i>
|Molecular Microbiology|2003|520
Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study
|Journal of Clinical Oncology|2019|490
Development of Sodium‐Sulfur Batteries
|International Journal of Applied Ceramic Technology|2004|354